Crossmark

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Crossref DOI link: https://doi.org/10.1038/s41392-025-02571-7

Published Online: 2026-02-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mao, Zekai

Peng, Juan

Cao, Yang

Wang, Na

Wang, Jue

Yang, Yang

Xu, Jinghuan

Meng, Fankai

Chen, Liting

Mao, Xia

Guo, Jiaqi

Zhou, Xiaoxi

Zhang, Yicheng

Wei, Jia https://orcid.org/0000-0002-6435-9368
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82070217)

National Natural Science Foundation of China (81873427)

Shenzhen Science and Technology Innovation Commission (GJHZ20220913143405011)
License Information

Text and Data Mining valid from 2026-02-13

Version of Record valid from 2026-02-13
More Information

Article History

Received: 28 July 2025

Revised: 30 November 2025

Accepted: 30 December 2025

First Online: 13 February 2026

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below